Mineralys insider plans sale of 16,236 shares

Mineralys Therapeutics, Inc. insider plans another stock sale under Rule 144.

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. insider plans another stock sale under Rule 144. A person identified as Jon Congleton has filed to sell 16,236 shares of Mineralys common stock through Merrill Lynch on or about 01/12/2026 on the NASDAQ, with an indicated aggregate market value of $529,639.50. These shares were acquired on 01/10/2026 through the vesting of a restricted stock unit award granted as part of the issuer’s equity compensation plan.

The notice also reports prior sales of Mineralys common stock during the past three months by the same seller, including 15,100 shares on 10/13/2025 for gross proceeds of $644,326.47 and 200,000 shares on 11/11/2025 for gross proceeds of $9,088,502.77. The filing lists 79,139,956 Mineralys common shares outstanding, providing context for the size of the planned sale.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing by MLYS insider Jon Congleton disclose?

The notice states that Jon Congleton plans to sell 16,236 shares of Mineralys Therapeutics, Inc. common stock under Rule 144.

How many Mineralys (MLYS) shares are planned to be sold and what is the value?

The filing covers 16,236 common shares with an indicated aggregate market value of $529,639.50, to be sold through Merrill Lynch.

When were the MLYS shares to be sold acquired and how?

The 16,236 shares were acquired on 01/10/2026 via vesting of a restricted stock unit award granted under the issuer’s equity compensation plan.

What past 3‑month Mineralys stock sales by this seller are reported?

The notice lists sales of 15,100 shares on 10/13/2025 for $644,326.47 and 200,000 shares on 11/11/2025 for $9,088,502.77 in gross proceeds.

On which exchange and through which broker are the MLYS shares expected to be sold?

The planned sale is listed for the NASDAQ through Merrill Lynch, located at 225 Liberty St, Floor 37, New York, NY 10281.

How many Mineralys Therapeutics common shares are reported outstanding in this notice?

The document notes 79,139,956 Mineralys Therapeutics common shares outstanding, giving context for the relative size of the planned sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/12/2026 - 04:23 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001644975
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Mineralys Therapeutics, Inc.
SEC File Number	001-41614
Address of Issuer	150 N. RADNOR CHESTER RD. SUITE F200 RADNOR PENNSYLVANIA 19087
Phone	(888) 378-6240
Name of Person for Whose Account the Securities are To Be Sold	Congleton Jon
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	16236	529639.50	79139956	01/12/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/10/2026	Vesting of restricted stock unit award	Mineralys Therapeutics, Inc.			16236	01/10/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Jon Congleton 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	10/13/2025	15100	644326.47
Jon Congleton 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	11/11/2025	200000	9088502.77

144: Remarks and Signature

Remarks
Date of Notice	01/12/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	01/28/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Jon Congleton
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)